NTBL NOTABLE LABS LTD

Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024

Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024

FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas Bock, M.D., Chief Executive Officer of Notable Labs, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024, taking place on May 13-14, 2024, in New York City.

Presentation Details:

Date:Monday, May 13, 2024
Time:12:30pm EST
Format:Fireside Chat
Webcast:
  

A live webcast of the fireside chat can be accessed under “” on the Notable website at . A replay of the webcast will be available on the Company’s website for approximately 90 days.

About Notable Labs, Ltd.

Notable Labs, Ltd. Is a clinical-stage platform therapeutics company developing predictive medicines for patients with cancer. Through its proprietary Predictive Medicine Platform (PMP), Notable aims to predict whether or not a patient is likely to respond to a specific therapeutic. The PMP is designed to identify and select clinically responsive patients prior to their treatment, potentially fast-tracking clinical development. By continually advancing and expanding the reach of the PMP across diseases and predicted medical outcomes, Notable aims to be the leader in predictive medicine and revolutionize the way patients seek and receive treatments that work best for them.

Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, with a greater likelihood of success, than traditional drug development. By transforming historical standards of care, Notable aims to create a dramatically positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California. Learn more at our website and follow us @notablelabs.

CONTACTS:

Investor Relations:

Daniel Ferry

LifeSci Advisors

+1 (617) 430-7576



EN
09/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NOTABLE LABS LTD

 PRESS RELEASE

Notable Labs to Participate in Fireside Chat at the Citizens JMP Secur...

Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024 FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas Bock, M.D., Chief Executive Officer of Notable Labs, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024, taking place on May 13-14, 2024, in New York C...

 PRESS RELEASE

Notable Labs Reports 2023 Financial Results and Provides a Business Up...

Notable Labs Reports 2023 Financial Results and Provides a Business Update FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the year ended December 31, 2023 and provided a business update. “The last year has been a time of great accomplishment for Notable. We built a strong clinical validation dataset, starting with a poster presented at the Ame...

 PRESS RELEASE

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Tri...

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid leukemia (AML) samples Plans to incorporate a dose optimization prelude to enhance patient response and tolerability also outlined in the poster FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), ...

 PRESS RELEASE

Notable Labs Presentation of Data Related to Innovations in the Use of...

Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented data related to innovations in the use of cryopreserved samples in the PPMP assay at the American Association for Cancer Research (AACR 2024) bei...

 PRESS RELEASE

Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. “We expect to initiate the Phase 2 program ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch